Drug Profile
BMS 986178
Alternative Names: BMS-986178; BMS-986178-01Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; National Cancer Institute (USA); Stanford University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported B-cell lymphoma
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 02 Aug 2021 Bristol-Myers Squibb completes a phase I/IIa trial in Advanced solid tumours in USA, Canada, Israel, Italy, Netherlands and Spain (NCT02737475) (EudraCT2015-004816-39)